Nizoral

Nizoral is a specialized brand under Kramer Laboratories, offering clinically effective anti-dandruff solutions through its flagship product, Nizoral® Anti-Dandruff Shampoo, which utilizes Ketoconazole for addressing fungal activity related to dandruff. Nizoral operates under Kramer Laboratories, Inc. , which manufactures the Nizoral® Anti-Dandruff Shampoo. The company is headquartered in Fort Washington, US.

In June 2018, Kramer Laboratories, a portfolio company of Avista Capital Partners and Dana Holdings, acquired Nizoral. This acquisition marked a strategic pivot for the company as it integrated Nizoral's unique product line into its offerings. Kramer Laboratories, the manufacturer of Nizoral® Anti-Dandruff Shampoo, offers a clinically proven product that contains Ketoconazole, a potent antifungal agent. This unique formulation is designed to effectively tackle the root cause of dandruff by controlling the fungal activity that leads to symptoms such as flaking, scaling, and itching.

Nizoral® is the only over-the-counter shampoo on the market with this active ingredient, emphasizing its distinction among other dandruff treatments. The product is targeted towards individuals suffering from dandruff, catering to a wide demographic that includes various age groups and skin types. Nizoral® is primarily available in North American and European markets, ensuring broad accessibility for consumers seeking relief from dandruff-related issues. Kramer Laboratories generates revenue through direct sales of its Nizoral® Anti-Dandruff Shampoo, which is distributed via retail channels, including pharmacies and supermarkets, as well as online platforms.

Transactions typically occur on a B2C model, where individual customers purchase the shampoo for personal use, addressing their specific dandruff concerns. The pricing structure for Nizoral® reflects its positioning as a premium product in the anti-dandruff segment, appealing to consumers who prioritize effective treatment options. Given its unique formulation, Nizoral® commands a competitive price point in the market, reinforcing its value proposition to end-users seeking reliable and clinically effective solutions for dandruff. Following the acquisition on June 21, 2018, Kramer Laboratories plans to leverage its resources to enhance Nizoral's market presence.

Future initiatives include the development of new product variations designed to address specific scalp health concerns, scheduled for launch in the upcoming year. The company is also targeting expansion into Asian markets, particularly in countries like Japan and South Korea, aiming for a launch by the end of 2024. The recent funding will be employed to facilitate these product developments and market expansions.